TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Count of bacteria (Streptococcus mutans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and efficacy markers
Endpoint domain: Adverse events/effects
Primary endpoint: Average sit-to-stand transition time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory variables related to coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serious adverse events (SAEs) in connection to blood sampling procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of OCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case Fatality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Levels of Various biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxidative-reduction homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of thoracentesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage change in number of intestinal drug transporters and enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in MSIS-29 scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Titer of Subclass of IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to medical attendance for acute gastroenteritis or acute diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of anti-rotavirus IgA seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Functional Health/Well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pentacam Nuclear Density Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropathic Pain Scale - Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory - Worst Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Traumatic Stress Disorder (PTSD) Total Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of NOVOCART® Basic
Endpoint domain: Adverse events/effects
Primary endpoint: Bladder discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV-DNA positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in average monthly number of infant DBS HIV tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in average monthly number of maternal postpartum HIV tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in average monthly number of DPT1 doses administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in pulse wave attenuation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total number of T-1-weighted Gd-enhanced lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Global CFR
Endpoint domain: Mortality/survival
Primary endpoint: 60-day All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving physical activity program recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Graft Contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Aged 6 Months to < 9 Years Who Provided Serum Samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Aged >= 65 Years Who Provided Serum Samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical Functioning Inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Severe Oral Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in postprandial insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lean mass percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral for Implantable Cardioverter Defibrillator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Dyadic Adjustment Scale (DAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Personal Assessment of Intimacy in Relationships scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Production of antigen-specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cerebral Blood Flow (rCBF) at Stimulation Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 2-back Minus 1-back Blood Oxygen Level-Dependent (BOLD) Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy to 2-back
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Need for mechanical ventilation or ICU admission or death
Endpoint domain: Mortality/survival
Primary endpoint: cerebro-cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Motor UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Transfusion need
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma metanephrine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma normetanephrine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in muscle metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vineland Adaptive Behavior Scales: Expanded Edition (VABS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peabody Picture Vocabulary Test (PPVT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: High Sensitivity Troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % lactulose excretion after 4 weeks of supplementary feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16S rRNA relative abundance of bacterial taxa after 4 weeks of supplementary feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-vaccination titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Acuity (Snellen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean CogState Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in quadriceps muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HAM-D-21 improvement >50% at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final HAM-D-21 total <7 at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predicted effect site concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consonant-Nucleus-Consonant (CNC) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with suture removal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Achieve Glycemic Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mini-BESTest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative residual curarisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: meropenem pancreatic tissue penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCVA Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal biomechanical changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial complication
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality at 1 month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Days Goal Met
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of fracture site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Calcium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypokalemia
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in T1 Lesion Relaxation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Evaluation of pulp for inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Evaluation of pulp for calcified bridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Evaluation of pulp for odontoblast layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from major adverse events (MAE) at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Technical success rate of implantation of the investigation device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Uptake of rapid SARS-CoV-2 testing strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Thickness of retinal layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flow-mediated Vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Pre-operative Baseline Speech Understanding in Quiet at 6 Months Post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Pre-operative Baseline Speech Understanding in Noise at 6 Months Post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Showing Post-operative Improvement in the Ipsilateral Ear in Quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity score differentiation
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of defective DNA mismatch repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Total OCA at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of Total OCA at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in P50 Ratio S2/S1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Agreement between virtual and in-person airway examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep efficiency scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Numbers of patients with spontaneous shunt closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients developing one or more complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients undergoing preemptive closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Mitochondrial Respiration in Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Cytochrome Oxidase (COX) in Muscle Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Citrate Synthase (CS) Enzymes in Muscle Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Mitochondrial DNA Content in Muscle Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tooth shade change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Ultraphonic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: High sensitivity Troponin I (hs-TnI) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N-terminal pro b-type natriuretic peptide (NTproBNP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Receiving Various Chemotherapy Regimens
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants who Received Chemotherapy Regimens as per National Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants who Received Radiotherapy Including Site (Extended/Involved) and Total Dosing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maternal and fetal morbimortality score
Endpoint domain: Mortality/survival
Primary endpoint: GVHD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of adverse events and toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarker of OPB-111077
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin action and response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: body composition adjustments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine levels in bronchial epithelial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical resolution of acute viral conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine net acid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VGPR or better response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory status of visceral adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: vascular cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: post-stroke depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: post-stroke apathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxford Hip Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Radiologic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with IGA 0 to 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm infant intake of mother's milk post-hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Binding potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-power of occipital leads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from Target Lesion Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: relapse rate in MRD+ patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate in MRD- patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of irAEs
Endpoint domain: Adverse events/effects
Primary endpoint: volume blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete aneurysm occlusion at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the ratio of fasting blood concentrations oxidized LDL / total LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Erythropoietin Dose Per Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Villous Architecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC [0-Inf]) of Total Drug-related Material in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Status at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS (depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HAM-A (anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CERAD (cognitive test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: WOMAC hip score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Retinal capillary plexus changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Mucus and Mucin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fugl-Myer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental State Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 10-Meter Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on the Brief Pain Inventory (BPI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: clinician-reported medical errors
Endpoint domain: Adverse events/effects
Primary endpoint: sore throat after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: BDPP effect on mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BDPP effect on cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Modulation of the ki-67 labeling index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypic modulation of the bronchial histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: presence of ocular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D nutritional status of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anthropometric measurements of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle stiffness from the biceps brachii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes